Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The Bespoke Gene Therapy Consortium: facilitating development of AAV gene therapies for rare diseases
A public–private partnership managed by the FNIH aims to address biological, manufacturing and regulatory challenges to the development of gene therapies for rare diseases.
According to recent estimates, there are more than 10,000 known human diseases that are considered rare — defined as affecting fewer than 200,000 people in the USA1. Collectively, these diseases affect upwards of 450 million people worldwide2. About 80% of rare diseases are monogenic, in which known alterations in a single gene are responsible for the clinical manifestations that result in significant morbidity and mortality. Monogenic diseases are potential candidates for gene therapies because the defective gene can be corrected or replaced, thereby restoring gene function to levels that show clinical benefit and arresting or reversing the disease state. Adeno-associated virus (AAV) gene therapies have the potential to provide long-term benefit for patients with diseases for which there currently are no treatments — a prospect that would be transformational in the treatment of many serious and life-threatening rare disorders3. However, many of these disorders are so rare, and the cost of development of gene therapy treatments is so high, that they are currently of no commercial interest.
Prices may be subject to local taxes which are calculated during checkout
Nature Reviews Drug Discovery23, 157-158 (2024)
doi: https://doi.org/10.1038/d41573-024-00020-8
Updates & Corrections
Correction 08 February 2024: The version of the article originally published online incorrectly stated that the BGTC was established by the FNIH. This has now been corrected.
T.M.M. is an employee of Thermo Fisher and owns stock in the company. J.S. is an employee of Biogen and owns stock in the company. L.C.S. and T.K.M. are employees of Novartis and own stock in the company. S.H.K. is an employee of Danaher.